Zacks Investment Research

Selected news for the capital firm - Zacks Investment Research, collected since 10/2017. Recent stories appear in Mayfield Recorder and com-unik.info. This capital firm shares healthcare news with Oncology, Medical Research, Biotech, Inovalon, Tabula Rasa HealthCare and hundreds of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
7/21/2021 $30.13 Billion in Sales Expected for Centene Co. (NYSE:CNC) This Quarter Mayfield Recorder Equities analysts forecast that Centene Co. (NYSE:CNC) will announce $30.13 billion in sales for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Centene’s earnings. The lowest sales estimate is $29.90 billion and the highest is $30.30 billion. Centene reported sales of $27.71 billion in the same quarter last year, which indicates a positive year over year growth rate of 8.7%. The company is ...
7/21/2021 Centene Co. (NYSE:CNC) Expected to Post Quarterly Sales of $30.13 Billion com-unik.info ... year, with estimates ranging from $120.84 billion to $121.68 billion. For the next year, analysts anticipate that the business will post sales of $124.80 billion, with estimates ranging from $124.08 billion to $126.17 billion. Zacks Investment Research ’s sales calculations are an average based on a survey of sell-side analysts that cover Centene. Centene (NYSE:CNC) last issued its quarterly earnings results on Monday, April 26th. The company reported ...
7/21/2021 Centene Co. (NYSE:CNC) Expected to Post Quarterly Sales of $30.13 Billion thelincolnianonline.com Wall Street analysts expect that Centene Co. (NYSE:CNC) will report $30.13 billion in sales for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Centene’s earnings, with the lowest sales estimate coming in at $29.90 billion and the highest estimate coming in at $30.30 billion. Centene reported sales of $27.71 billion during the same quarter last year, which indicates a positive year-over-year ...
7/21/2021 GoHealth (NASDAQ:GOCO) Hits New 12-Month Low at $9.57 - Ticker Report Ticker Report ... report on Friday, May 14th. Raymond James decreased their price target on GoHealth from $15.00 to $14.00 and set an “outperform” rating for the company in a report on Monday, May 17th. Finally, Zacks Investment Research raised GoHealth from a “sell” rating to a “hold” rating in a report on Monday, May 17th. Two equities research analysts have rated the stock with a hold rating and eleven ...
7/21/2021 GoHealth (NASDAQ:GOCO) Sets New 52-Week Low at $9.57 - Watch List News watchlistnews.com ... research report on Monday, May 17th. Truist reduced their price target on GoHealth from $26.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, May 13th. Zacks Investment Research upgraded GoHealth from a “sell” rating to a “hold” rating in a research report on Monday, May 17th. Finally, Raymond James reduced their price target on GoHealth from $15.00 to $14.00 ...
7/21/2021 1Life Healthcare (NASDAQ:ONEM) Sets New 12-Month Low at $25.30 zolmax.com ... on Thursday, May 13th. KeyCorp assumed coverage on shares of 1Life Healthcare in a research report on Friday, May 21st. They issued an “overweight” rating and a $41.00 price objective on the stock. Zacks Investment Research cut shares of 1Life Healthcare from a “hold” rating to a “sell” rating in a research report on Friday, June 11th. Credit Suisse Group reduced their price target on shares of ...
7/21/2021 Medicaid growth helps insurer Anthem beat Q2 expectations SFGate ... and adjusted earnings totaled $7.03 per share. Operating revenue, which excludes investment income, rose 14% to $33.28 billion.Analysts expected, on average, earnings of $6.34 per share on $33.15 billion in revenue, according to Zacks Investment Research .Indianapolis-based Anthem Inc. covers more than 43 million people in several states, including big markets like New York and California. Its IngenioRx business also brought in about $6.2 billion in revenue during ...
7/21/2021 Medicaid growth helps insurer Anthem beat Q2 expectations mynorthwest.com ... and adjusted earnings totaled $7.03 per share. Operating revenue, which excludes investment income, rose 14% to $33.28 billion. Analysts expected, on average, earnings of $6.34 per share on $33.15 billion in revenue, according to Zacks Investment Research . Indianapolis-based Anthem Inc. covers more than 43 million people in several states, including big markets like New York and California. Its IngenioRx business also brought in about $6.2 billion in revenue during ...
7/21/2021 Tivity Health, Inc. (NASDAQ:TVTY) Expected to Post Earnings of $0.35 Per Share rivertonroll.com Wall Street analysts expect Tivity Health, Inc. (NASDAQ:TVTY) to report earnings of $0.35 per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Tivity Health’s earnings, with the highest EPS estimate coming in at $0.38 and the lowest estimate coming in at $0.31. Tivity Health posted earnings of $0.79 per share in the same quarter last year, which indicates a negative ...
7/21/2021 Zacks: Analysts Anticipate Tivity Health, Inc. (NASDAQ:TVTY) to Post $0.35 Earnings Per Share slatersentinel.com Analysts expect that Tivity Health, Inc. (NASDAQ:TVTY) will announce $0.35 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Tivity Health’s earnings, with the lowest EPS estimate coming in at $0.31 and the highest estimate coming in at $0.38. Tivity Health reported earnings per share of $0.79 in the same quarter last year, which suggests a negative year-over ...
7/21/2021 Medicaid growth helps insurer Anthem beat Q2 expectations | Stock Market | lancasteronline.com lancasteronline.com ... and adjusted earnings totaled $7.03 per share. Operating revenue, which excludes investment income, rose 14% to $33.28 billion. Analysts expected, on average, earnings of $6.34 per share on $33.15 billion in revenue, according to Zacks Investment Research . Indianapolis-based Anthem Inc. covers more than 43 million people in several states, including big markets like New York and California. Its IngenioRx business also brought in about $6.2 billion in revenue during ...
7/21/2021 $564.66 Million in Sales Expected for Amedisys, Inc. (NASDAQ:AMED) This Quarter - Ticker Report Ticker Report Wall Street analysts predict that Amedisys, Inc. (NASDAQ:AMED) will post $564.66 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Amedisys’ earnings. The highest sales estimate is $571.04 million and the lowest is $555.34 million. Amedisys reported sales of $485.06 million in the same quarter last year, which would indicate a positive year over year growth rate of 16.4%. The ...
7/20/2021 Eli Lilly and (NYSE:LLY) Rating Lowered to Sell at Zacks Investment Research Mayfield Recorder ... Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. Featured Story: Analyst Ratings Trading Get a free copy of the Zacks research report on Eli Lilly and (LLY) For more information about research offerings from Zacks Investment Research, visit http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1 Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings ...
7/20/2021 Afya (NASDAQ:AFYA) Downgraded by Zacks Investment Research to Hold com-unik.info ... to third-party medical schools. Featured Article: Should I follow buy, hold and sell recommendations? Get a free copy of the Zacks research report on Afya (AFYA) For more information about research offerings from Zacks Investment Research, visit http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1 Afya Afya basic/?symbol=NASDAQ:AFYA&c=Afya ...
7/20/2021 Antares Pharma (NASDAQ:ATRS) Earns Buy Rating from Analysts at Truist baseballnewssource.com ... note published on Friday, The Fly reports. The brokerage issued a buy rating and a $7.00 price target on the specialty pharmaceutical company’s stock. Several other research analysts also recently commented on ATRS. Zacks Investment Research raised shares of Antares Pharma from a sell rating to a hold rating in a research note on Wednesday, July 7th. HC Wainwright lifted their target price on shares of Antares Pharma from ...
7/20/2021 Antares Pharma (NASDAQ:ATRS) Now Covered by Analysts at Truist - Mayfield Recorder Mayfield Recorder ... also recently issued reports about the company. HC Wainwright upped their target price on Antares Pharma from $4.50 to $5.00 and gave the company a buy rating in a report on Monday, May 10th. Zacks Investment Research upgraded Antares Pharma from a sell rating to a hold rating in a report on Wednesday, July 7th. One investment analyst has rated the stock with a hold rating and five have assigned ...
7/20/2021 Walker & Dunlop (NYSE:WD) Downgraded by Zacks Investment Research theenterpriseleader.com ... and bridge/interim loans. Featured Article: Can individual investors take part in an IPO? Get a free copy of the Zacks research report on Walker & Dunlop (WD) For more information about research offerings from Zacks Investment Research, visit http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1 Receive News & Ratings for Walker & Dunlop Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ...
7/20/2021 Analysts Anticipate Heska Co. (NASDAQ:HSKA) Will Post Quarterly Sales of $56.63 Million American Banking News ... with estimates ranging from $234.93 million to $241.80 million. For the next fiscal year, analysts expect that the company will report sales of $264.83 million, with estimates ranging from $257.87 million to $271.22 million. Zacks Investment Research ’s sales calculations are an average based on a survey of analysts that that provide coverage for Heska. Heska (NASDAQ:HSKA) last posted its quarterly earnings data on Thursday, May 6th. The medical ...
7/20/2021 $1.01 Earnings Per Share Expected for Encompass Health Co. (NYSE:EHC) This Quarter baseballnewssource.com Brokerages expect that Encompass Health Co. (NYSE:EHC) will post $1.01 earnings per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Encompass Health’s earnings, with the highest EPS estimate coming in at $1.02 and the lowest estimate coming in at $0.98. Encompass Health posted earnings of $0.31 per share during the same quarter last year, which would suggest a positive year-over ...
7/20/2021 $4.07 Million in Sales Expected for Sensus Healthcare, Inc. (NASDAQ:SRTS) This Quarter baseballnewssource.com Equities research analysts expect Sensus Healthcare, Inc. (NASDAQ:SRTS) to report sales of $4.07 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Sensus Healthcare’s earnings. The lowest sales estimate is $3.84 million and the highest is $4.38 million. Sensus Healthcare reported sales of $1.18 million during the same quarter last year, which would suggest a positive year-over-year growth rate ...